Most patients with HoFH respond moderately to statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors depending on LDL receptor (LDLR) activity [27]. This evidence concerns the gene LDLR and homozygous familial hypercholesterolemia.